Specialty clinical laboratory Cleveland HeartLab Inc. has completed a $14.7- million financing round. While Mutual Capital Partners, Cleveland, led the round, existing shareholders Excel Venture Management and Cleveland Clinic also participated. The Cleveland-based laboratory, which also describes itself as a cardiovascular disease management company, has developed tests that practitioners use to manage and prevent heart disease. The company’s research and development lab reportedly develops next-generation cardiovascular disease biomarkers. According to company President and CEO Jake Orville, “This financing will support the development and commercialization of our pipeline of new biomarkers, making our approach even stronger and enabling us to continue our leadership in cardiovascular and chronic disease management. Together, the work supported by this round will allow us to develop even greater breadth and depth in our test offerings and will strengthen our ability to reach and retain key customers.” See Cleveland HeartLab News Release, October 22, 2012.